FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100096299> ?p ?o ?g. }

• W2100096299 endingPage "1844" @default.
• W2100096299 startingPage "1838" @default.
• W2100096299 abstract "ABSTRACT Hepatitis C virus (HCV) protease inhibitors combined with pegylated alfa interferon-ribavirin have demonstrated improved efficacy compared with pegylated alfa interferon-ribavirin alone for the treatment of chronic hepatitis C. Asunaprevir (BMS-650032), a novel HCV NS3 protease inhibitor in clinical development, was evaluated for safety, antiviral activity, and resistance in four double-blind, placebo-controlled, sequential-panel, single- and multiple-ascending-dose (SAD and MAD) studies in healthy subjects or subjects with chronic HCV genotype 1 infection. In SAD studies, subjects (healthy or with chronic HCV infection) were randomized to receive asunaprevir in dose groups of 10 to 1,200 mg or a placebo. In MAD studies, healthy subjects were randomized to receive asunaprevir in dose groups of 10 to 600 mg twice daily or a placebo for 14 days; subjects with HCV infection received asunaprevir in dose groups of 200 to 600 mg twice daily, or a placebo, for 3 days. Across all four studies, headache and diarrhea were the most frequent adverse events in asunaprevir recipients. Asunaprevir at doses of 200 to 600 mg resulted in rapid HCV RNA decreases from the baseline; maximal mean changes in HCV RNA over time were 2.7 and 3.5 log 10 IU/ml in the SAD and MAD studies, respectively. No enrichment of signature asunaprevir-resistant viral variants was detected. In conclusion, the novel NS3 protease inhibitor asunaprevir, when administered at single or multiple doses of 200 to 600 mg twice daily, is generally well tolerated, achieving rapid and substantial decreases in HCV RNA levels in subjects chronically infected with genotype 1 HCV." @default.
• W2100096299 created "2016-06-24" @default.
• W2100096299 creator A5011922070 @default.
• W2100096299 creator A5020747557 @default.
• W2100096299 creator A5028366409 @default.
• W2100096299 creator A5033179964 @default.
• W2100096299 creator A5041269947 @default.
• W2100096299 creator A5054070286 @default.
• W2100096299 creator A5054722909 @default.
• W2100096299 creator A5054886794 @default.
• W2100096299 creator A5059857190 @default.
• W2100096299 creator A5060169505 @default.
• W2100096299 creator A5064109310 @default.
• W2100096299 creator A5065810522 @default.
• W2100096299 creator A5068871718 @default.
• W2100096299 creator A5070844976 @default.
• W2100096299 creator A5075322332 @default.
• W2100096299 creator A5075976742 @default.
• W2100096299 creator A5085215760 @default.
• W2100096299 creator A5086579034 @default.
• W2100096299 creator A5087714251 @default.
• W2100096299 creator A5089047789 @default.
• W2100096299 creator A5091414363 @default.
• W2100096299 date "2012-04-01" @default.
• W2100096299 modified "2023-10-18" @default.
• W2100096299 title "Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C" @default.
• W2100096299 cites W1979574442 @default.
• W2100096299 cites W2001129358 @default.
• W2100096299 cites W2004440658 @default.
• W2100096299 cites W2015216410 @default.
• W2100096299 cites W2017972113 @default.
• W2100096299 cites W2033595149 @default.
• W2100096299 cites W2046658390 @default.
• W2100096299 cites W2064569884 @default.
• W2100096299 cites W2072292444 @default.
• W2100096299 cites W2075282196 @default.
• W2100096299 cites W2106927931 @default.
• W2100096299 cites W2117718017 @default.
• W2100096299 cites W2119819445 @default.
• W2100096299 cites W2125963799 @default.
• W2100096299 cites W2141214317 @default.
• W2100096299 cites W2143559032 @default.
• W2100096299 cites W2161070289 @default.
• W2100096299 cites W2163606686 @default.
• W2100096299 cites W2171945301 @default.
• W2100096299 doi "https://doi.org/10.1128/aac.05854-11" @default.
• W2100096299 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3318341" @default.
• W2100096299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22290978" @default.
• W2100096299 hasPublicationYear "2012" @default.
• W2100096299 type Work @default.
• W2100096299 sameAs 2100096299 @default.
• W2100096299 citedByCount "51" @default.
• W2100096299 countsByYear W21000962992012 @default.
• W2100096299 countsByYear W21000962992013 @default.
• W2100096299 countsByYear W21000962992014 @default.
• W2100096299 countsByYear W21000962992015 @default.
• W2100096299 countsByYear W21000962992016 @default.
• W2100096299 countsByYear W21000962992017 @default.
• W2100096299 countsByYear W21000962992018 @default.
• W2100096299 countsByYear W21000962992019 @default.
• W2100096299 countsByYear W21000962992020 @default.
• W2100096299 countsByYear W21000962992021 @default.
• W2100096299 countsByYear W21000962992023 @default.
• W2100096299 crossrefType "journal-article" @default.
• W2100096299 hasAuthorship W2100096299A5011922070 @default.
• W2100096299 hasAuthorship W2100096299A5020747557 @default.
• W2100096299 hasAuthorship W2100096299A5028366409 @default.
• W2100096299 hasAuthorship W2100096299A5033179964 @default.
• W2100096299 hasAuthorship W2100096299A5041269947 @default.
• W2100096299 hasAuthorship W2100096299A5054070286 @default.
• W2100096299 hasAuthorship W2100096299A5054722909 @default.
• W2100096299 hasAuthorship W2100096299A5054886794 @default.
• W2100096299 hasAuthorship W2100096299A5059857190 @default.
• W2100096299 hasAuthorship W2100096299A5060169505 @default.
• W2100096299 hasAuthorship W2100096299A5064109310 @default.
• W2100096299 hasAuthorship W2100096299A5065810522 @default.
• W2100096299 hasAuthorship W2100096299A5068871718 @default.
• W2100096299 hasAuthorship W2100096299A5070844976 @default.
• W2100096299 hasAuthorship W2100096299A5075322332 @default.
• W2100096299 hasAuthorship W2100096299A5075976742 @default.
• W2100096299 hasAuthorship W2100096299A5085215760 @default.
• W2100096299 hasAuthorship W2100096299A5086579034 @default.
• W2100096299 hasAuthorship W2100096299A5087714251 @default.
• W2100096299 hasAuthorship W2100096299A5089047789 @default.
• W2100096299 hasAuthorship W2100096299A5091414363 @default.
• W2100096299 hasBestOaLocation W21000962991 @default.
• W2100096299 hasConcept C126322002 @default.
• W2100096299 hasConcept C132379496 @default.
• W2100096299 hasConcept C142724271 @default.
• W2100096299 hasConcept C159047783 @default.
• W2100096299 hasConcept C203014093 @default.
• W2100096299 hasConcept C204787440 @default.
• W2100096299 hasConcept C2522874641 @default.
• W2100096299 hasConcept C27081682 @default.
• W2100096299 hasConcept C2776408679 @default.
• W2100096299 hasConcept C2776455275 @default.
• W2100096299 hasConcept C2776461080 @default.
• W2100096299 hasConcept C2776979040 @default.

• next